Biospace’s InBody device is drawing attention from consumers at home and abroad as an obesity prevention tool.

The world’s first body composition analysis device that uses an eight-point tactile electrode method, InBody has received regulatory approval from the U.S. Food and Drug Administration and in other countries such as Japan.

The device gives readings for the percentage of a person’s weight accounted for by fat, muscle, free fluid and other variables.

Biospace has performed clinical tests on some 20,000 foreign subjects, including U.S. citizens, as well as Koreans. The diversity of the subjects serves as a basis for the accuracy of the InBody body composition assessment.

The company, founded in 1996, opened a plant specializing in body composition analyzers in Cheonan, South Chungcheong Province, in 2004.

With the InBody’s unrivaled position in the domestic market, it has solidified its status as professional medical device manufacturer.

It participated in Arab Health 2012 in Dubai, United Arab Emirates. At the exhibition, it showcased several models ― InBody720, InBody230, BPBIO320 and BMS370.

“We attracted lots of people due to its precise and accurate performance. Not only were people from Arabic countries interested in the devices, but people from other places around the world were also willing to know more about InBody,” a company spokesman said.

It also attended the FIBO 2011 in Essen, Germany. It unveiled the InBody170, which was developed to provide high-quality equipment at a more affordable price. InBody720, InBody520, InBody230 were also exhibited.

By Kim Yon-se (kys@heraldcorp.com)